News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Flamel Technologies (FLML) Announces Projected Release Date of Fourth Quarter and Year-End 2011 Results; Additional Releases; Conference Call



3/14/2012 8:39:54 AM

LYON, FRANCE--(Marketwire - March 13, 2012) - Flamel Technologies (NASDAQ: FLML) expects to release its financial results for the fourth quarter and the fiscal year 2011, as well as additional releases, on Wednesday, March 14th, after the market close. A conference call to discuss these results as well as additional releases has been scheduled for Thursday, March 15th, at 8:30 AM (Eastern Daylight Time). A question and answer period is scheduled to follow management's prepared remarks.

To participate in the conference call, investors are invited to dial 1-888-256-9132. The conference ID number is 4062934. The conference call webcast may be accessed at www.flamel.com.

About Flamel Technologies. Flamel Technologies SA (NASDAQ: FLML) is a leading drug delivery company focused on the goal of developing safer, more efficacious formulations of drugs that address unmet medical needs. Its product development pipeline includes biological and chemical drugs formulated with the Medusa® and Micropump® proprietary platforms. Several Medusa-based products are at various clinical stages of development; Medusa's lead internal product candidate IFN-alpha XL (long-acting interferon alpha-2b) is being evaluated in a Phase 2a trial in HCV patients. The Company has developed approved products and manufactures Micropump-based microparticles under FDA-audited GMP guidelines. Flamel Technologies has collaborations with a number of leading pharmaceutical and biotechnology companies, including GlaxoSmithKline plc (Coreg CR®, carvedilol phosphate) and Merck Serono S.A. (long acting interferon beta-1a). Additional information can be found at www.flamel.com.

This document contains a number of matters that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. This release reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2010.



Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES